4.85
Nuvation Bio Inc stock is traded at $4.85, with a volume of 9.60M.
It is up +10.48% in the last 24 hours and up +49.69% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$4.39
Open:
$4.42
24h Volume:
9.60M
Relative Volume:
1.51
Market Cap:
$1.66B
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-13.86
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
+42.23%
1M Performance:
+49.69%
6M Performance:
+127.70%
1Y Performance:
+110.87%
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NUVB
Nuvation Bio Inc
|
4.85 | 1.50B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Key metrics from Nuvation Bio Inc.’s quarterly dataProduct Launch & Reliable Entry Point Alerts - newser.com
How Nuvation Bio Inc. Warrants stock compares with tech leadersPortfolio Update Summary & Low Drawdown Trading Strategies - newser.com
Sector ETF performance correlation with Nuvation Bio Inc.Insider Selling & High Yield Stock Recommendations - newser.com
Will Nuvation Bio Inc. price bounce be sustainableMarket Movement Recap & Detailed Earnings Play Alerts - newser.com
How Nuvation Bio Inc. Warrants stock behaves in tightening cyclesQuarterly Profit Review & Community Consensus Trade Signals - newser.com
Can Nuvation Bio Inc. stock deliver surprise earnings beat2025 Breakouts & Breakdowns & Advanced Technical Signal Analysis - newser.com
Is Nuvation Bio Inc. Warrants stock undervalued after correctionMarket Sentiment Summary & Daily Profit Focused Screening - newser.com
How big funds are accumulating Nuvation Bio Inc. Warrants stockWeekly Stock Report & Daily Profit Maximizing Tips - newser.com
Nuvation Bio Inc. Class A (NUVB) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Why Nuvation Bio Inc. stock is a must watch in 2025Market Trend Report & Fast Moving Stock Trade Plans - newser.com
Has Nuvation Bio Inc. found a price floor2025 Institutional Moves & Accurate Trade Setup Notifications - newser.com
Nuvation Bio enrolls first patient in phase 3 trial for glioma treatment - Investing.com Canada
Nuvation Bio enrolls first patient in phase 3 trial for glioma treatment By Investing.com - Investing.com South Africa
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma - Investing News Network
Will Nuvation Bio Inc. Warrants stock announce a stock splitJuly 2025 Levels & Expert Verified Movement Alerts - newser.com
Chart based exit strategy for Nuvation Bio Inc.Bull Run & Risk Controlled Stock Pick Alerts - newser.com
Real time pattern detection on Nuvation Bio Inc. stockWeekly Profit Summary & Consistent Return Investment Signals - newser.com
Nuvation Bio stock hits 52-week high at 4.09 USD By Investing.com - Investing.com Nigeria
Can Nuvation Bio Inc. Class stock resist broad market declinesWeekly Risk Report & AI Powered Trade Plan Recommendations - newser.com
Is Nuvation Bio Inc. stock ready for a breakoutJuly 2025 Update & Trade Opportunity Analysis - newser.com
Has Nuvation Bio Inc. formed a bullish divergenceWeekly Market Report & Verified Stock Trade Ideas - newser.com
Nuvation Bio Inc. (NUVB) Stock Price, News, Quote & History - Yahoo
Nuvation Bio stock hits 52-week high at 4.09 USD - Investing.com India
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 - BioSpace
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):